Medical News

RSS
New article finds no compelling evidence for withdrawing nitrous oxide from operating theaters

New article finds no compelling evidence for withdrawing nitrous oxide from operating theaters

Secret to the life-long activity of a stem cell niche

Secret to the life-long activity of a stem cell niche

Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015

Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015

PGDx introduces ImmunoSelect-R service to support development of immuno-oncology cancer therapies

PGDx introduces ImmunoSelect-R service to support development of immuno-oncology cancer therapies

MHICN expands clinical research program in collaboration with Erasmus Medical Center and ErasmusAGE

MHICN expands clinical research program in collaboration with Erasmus Medical Center and ErasmusAGE

Study: Removing more tissue during partial mastectomy could reduce need for second surgery

Study: Removing more tissue during partial mastectomy could reduce need for second surgery

Alternative rehabilitation program for women diagnosed with diastasis recti

Alternative rehabilitation program for women diagnosed with diastasis recti

CHEMOSAT treatment of UM patients with hepatic metastases highlighted at ASCO 2015

CHEMOSAT treatment of UM patients with hepatic metastases highlighted at ASCO 2015

Caris Molecular Intelligence allows comparisons between tumors sharing histological features

Caris Molecular Intelligence allows comparisons between tumors sharing histological features

Smartphone digital ruler ensures correctly-fitting condom

Smartphone digital ruler ensures correctly-fitting condom

Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes  in CLL/SLL patients

Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes in CLL/SLL patients

Study findings underscore importance of PD-1/PD-L1 expression in oncogenic signaling pathways

Study findings underscore importance of PD-1/PD-L1 expression in oncogenic signaling pathways

Researchers identify key driver mutations in glioma samples that confirm tumor heterogeneity

Researchers identify key driver mutations in glioma samples that confirm tumor heterogeneity

Lancet Diabetes & Endocrinology to publish paper on eGFR and albuminuria for prediction of cardiovascular outcomes

Lancet Diabetes & Endocrinology to publish paper on eGFR and albuminuria for prediction of cardiovascular outcomes

COSMED USA selected to provide body composition testing at 2015 NHL Scouting Combine

COSMED USA selected to provide body composition testing at 2015 NHL Scouting Combine

OncoGenex's Phase 3 SYNERGY trial shows survival benefits of custirsen therapy in CRPC patients with poor prognosis

OncoGenex's Phase 3 SYNERGY trial shows survival benefits of custirsen therapy in CRPC patients with poor prognosis

ESMO-MCBS: A standard tool to assist oncology clinicians evaluate effective anti-cancer medicines

ESMO-MCBS: A standard tool to assist oncology clinicians evaluate effective anti-cancer medicines

Nanopatch Jet Coating drug delivery platform wins 2015 Good Design Award

Nanopatch Jet Coating drug delivery platform wins 2015 Good Design Award

Epic Sciences presents single cell sequencing data from mCRPC patients at 2015 ASCO

Epic Sciences presents single cell sequencing data from mCRPC patients at 2015 ASCO

Additional preclinical data on DelMar’s VAL-083 to treat temozolomide-resistant GBM presented at AACR

Additional preclinical data on DelMar’s VAL-083 to treat temozolomide-resistant GBM presented at AACR

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.